The human body produces T cells to recognize and fight disease. Each T cell has a unique T cell receptor (or TCR) on its surface that surveils small fragments of proteins presented by other cells. Upon detecting evidence of cancer or infection, a subset of T cells binds the diseased cells and orchestrates their elimination. When tumors and infections cannot be eradicated naturally, researchers employ immunotherapies to boost the immune system’s effectiveness.
By inserting genes encoding a tumor-specific TCR into a patient’s T cells, researchers can engineer a large population of T cells to target tumor cells. This approach, called TCR gene therapy, has yielded clinical successes where conventional cancer treatments have failed. However, TCR gene therapy is not without risk. The introduced receptor can become tangled with the resident receptor in each engineered T cell, causing some of these cells to attack healthy cells. A new technique developed by Caltech researchers prevents this from happening, increasing the safety of TCR gene therapy.
Click here to Read the full article: Genetically engineering disease-fighting cells
Share this entry
- The American Health Council Appoints Dr. James Bashkin, D.Phil to the Physician Board March 31, 2020
- The American Health Council Appoints Dr. Robert W. Letton, MD to the Physician Board March 19, 2020
- The American Health Council Appoints Dr. Akwasi Adjei to the Industry Board January 17, 2020
- The American Health Council Appoints Dr. Nelson Leung to the Physician Board January 17, 2020
- The American Health Council Appoints Ms. Karie Soost to the Physician Board January 17, 2020
- The American Health Council Appoints Mr. Gregory King to the Industry Board January 17, 2020